Using a published protocol [23], we developed a panel of breast cancer PDOs with varying HER2 and ER/PR expression (Table 1) in order to test the effects of different anti-HER2 treatments and/or a ADAM10/17 inhibitor. Here, ADAM10 is linked to breast cancer.